Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
Acquired by private investors in 2020
|
| gptkbp:CEO |
gptkb:Dr._John_B._Simpson
|
| gptkbp:employees |
Approximately 50
|
| gptkbp:focus |
Peripheral artery disease
|
| gptkbp:founded |
2014
|
| gptkbp:founder |
gptkb:Dr._John_B._Simpson
|
| gptkbp:headquarters |
gptkb:Redwood_City,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Avinger, Inc.
|
| gptkbp:industry |
Medical Devices
|
| gptkbp:market |
gptkb:United_States
International |
| gptkbp:partnerships |
Various hospitals and clinics
|
| gptkbp:products |
gptkb:Ocelot_System
Lumivascular_Technology |
| gptkbp:regulatoryCompliance |
FDA_approved
|
| gptkbp:research |
Clinical trials
|
| gptkbp:stockExchange |
Yes
AVGR |
| gptkbp:technology |
Image-guided therapy
|
| gptkbp:website |
www.avinger.com
|